Lerociclib: Experimental Treatment for Epidermal Growth Factor Receptor mutant (EGFRm) Non-Small Cell Lung Cancer (NSCLC)

Scientific rationale and therapeutic potential

Lerociclib is a potent and selective oral CDK4/6 inhibitor designed to block the growth of cancer cells and induce tumor-cell death when combined with other anti-cancer agents, such as Tagrisso®. Lerociclib has the potential to be best-in-class versus other oral CDK4/6 inhibitors.

Preclinical rationale (see: Publications)

G1 is recruiting patients for a Phase 1b/2 trial in EGFRm NSCLC

G1T38-03 Trial  
  • EGFRm non-small cell lung cancer
  • multi-center, randomized, open-label
  • lerociclib + Tagrisso┬«
  • approximately 145 patients
  • ClinicalTrials.gov identifier: NCT03455829


Click here for printable version of our lerociclib EGFRm non-small cell lung cancer clinical trial fact sheet